Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Abstract Following publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All c...
Main Authors: | Simona Sacco, Lars Bendtsen, Messoud Ashina, Uwe Reuter, Gisela Terwindt, Dimos-Dimitrios Mitsikostas, Paolo Martelletti |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | The Journal of Headache and Pain |
Online Access: | http://link.springer.com/article/10.1186/s10194-019-0972-5 |
Similar Items
-
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Simona Sacco, et al.
Published: (2019-01-01) -
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
by: Lars Bendtsen, et al.
Published: (2018-09-01) -
Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
by: Paolo Martelletti, et al.
Published: (2019-05-01) -
Calcitonin Gene-Related Peptide in Tension-Type Headache
by: Messoud Ashina
Published: (2001-01-01) -
The changing faces of migraine
by: Paolo Martelletti, et al.
Published: (2019-05-01)